UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of May 2022

(Report No. 3)

 

Commission file number: 001-38041

 

SCISPARC LTD.

(Translation of registrant’s name into English)

 

20 Raul Wallenberg Street, Tower A,

Tel Aviv 6971916 Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

 

 

 

 

 

 

CONTENTS

 

On May 26, 2022, SciSparc Ltd. (the “Company”) issued a press release titled “SciSparc Announces Ethics Committee Approval to Conduct a Phase IIb Trial in Tourette Syndrome”. A copy of this press release is furnished herewith as Exhibit 99.1.

 

The first, third, fourth and fifth paragraphs and the section titled “Forward-Looking Statements” in the press release attached as Exhibit 99.1 are incorporated by reference into the registration statements on Form F-3 (File No. 333-233417 and File No. 333-248670) and on Form S-8 (File No. 333-225773) of the Company, filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

1

 

 

EXHIBIT INDEX

 

Exhibit No.    
99.1   Press release titled: “SciSparc Announces Ethics Committee Approval to Conduct a Phase IIb Trial in Tourette Syndrome”.

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  SciSparc Ltd.
   
Date: May 26, 2022 By: /s/ Oz Adler
    Name:  Oz Adler
    Title: Chief Executive Officer &
Chief Financial Officer

 

 

3

 

 

Therapix Biosciences (NASDAQ:TRPX)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Therapix Biosciences Charts.
Therapix Biosciences (NASDAQ:TRPX)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Therapix Biosciences Charts.